Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 11Osteoporosis 8Colorectal Neoplasms 4Bone Diseases, Metabolic 4Prostatic Neoplasms 3Pain 3Vitamin D Deficiency 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma 2Leukemia 2Colonic Neoplasms 2Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Polycystic Ovary Syndrome 1Pancreatic Neoplasms 1Paclitaxel-induced Neuropathy 1Ovarian Neoplasms 1Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Myocardial Ischemia 1Myelodysplastic Syndromes 1Multiple Myeloma 1Multiple Endocrine Neoplasia Type 1 1Motor Activity 1Lung Neoplasms 1Kidney Neoplasms 1Inflammation 1Heart Diseases 1Head and Neck Neoplasms 1

Interventions

Denosumab 7Zoledronic Acid 2Vitamin D 2Indocyanine Green 2gentamicin-polymethylmethacrylate bead 1fludarabine 1aldesleukin 1Nivolumab 1Ipilimumab 1Dasatinib 1Cyclophosphamide 1Calcium 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Giant Cell Tumor of Bone × Calcium × Clear all
NCT00396279 2022-11-08

Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone

Amgen

Phase 2 Completed
37 enrolled 13 charts

Giant Cell Tumor of Bone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡